Levodopa Patent Expiration
Levodopa is Used for managing off episodes in Parkinson's disease patients treated with carbidopa/levodopa through the inhalation of levodopa powder particles. It was first introduced by Hoffmann La Roche Inc
Levodopa Patents
Given below is the list of patents protecting Levodopa, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Inbrija | US12458615 | Methods For Providing Rapid Relief Of Motor Fluctuations In A Parkinson'S Disease Patient | Oct 21, 2033 | Merz |
| Inbrija | US8545878 | Capsules containing high doses of levodopa for pulmonary use | Nov 16, 2032 | Merz |
| Inbrija | US8685442 | Capsules containing high doses of levodopa for pulmonary use | Nov 16, 2032 | Merz |
| Inbrija | US8945612 | Capsules containing high doses of levodopa for pulmonary use | Nov 16, 2032 | Merz |
| Inbrija | US9393210 | Capsules containing high doses of levodopa for pulmonary use | Nov 16, 2032 | Merz |
| Inbrija | USRE43711 | Pulmonary delivery for levodopa | Feb 03, 2029 | Merz |
| Inbrija | US7182961 | Particulate compositions for pulmonary delivery |
Feb 22, 2024
(Expired) | Merz |
| Inbrija | US8404276 | Pulmonary delivery for levodopa |
Mar 19, 2023
(Expired) | Merz |
| Inbrija | US8586093 | Pulmonary delivery for levodopa |
Mar 19, 2023
(Expired) | Merz |
| Inbrija | US9155699 | Pulmonary delivery for levodopa |
Mar 19, 2023
(Expired) | Merz |
| Inbrija | US7384649 | Particulate compositions for pulmonary delivery |
Nov 20, 2022
(Expired) | Merz |
| Inbrija | US6858199 | High efficient delivery of a large therapeutic mass aerosol |
Nov 04, 2021
(Expired) | Merz |
| Inbrija | US7556798 | Highly efficient delivery of a large therapeutic mass aerosol |
Nov 04, 2021
(Expired) | Merz |
| Inbrija | US7146978 | Inhalation device and method |
Apr 16, 2021
(Expired) | Merz |
| Inbrija | US6514482 | Pulmonary delivery in treating disorders of the central nervous system |
Sep 19, 2020
(Expired) | Merz |
| Inbrija | US6613308 | Pulmonary delivery in treating disorders of the central nervous system |
Sep 19, 2020
(Expired) | Merz |
| Inbrija | US6979437 | Pulmonary delivery in treating disorders of the central nervous system |
Sep 19, 2020
(Expired) | Merz |
| Inbrija | US6921528 | Highly efficient delivery of a large therapeutic mass aerosol |
Jun 19, 2020
(Expired) | Merz |
| Inbrija | US8628754 | Highly efficient delivery of a large therapeutic mass aerosol |
Jun 19, 2020
(Expired) | Merz |
Levodopa's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Levodopa:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
